Novavax’s 3,500% Surge on a Covid-19 Vaccine Faces First Test
- Short sellers rack up over $1 billion in 2020 losses, S3 says
- Biotech’s Covid-19 data expected by the end of the month
Three potential Covid-19 vaccines are seen at Novavax labs in Rockville, Maryland, on March 20.
Photographer: Andrew Caballero-Reynolds/AFP via Getty Images
This article is for subscribers only.
Novavax Inc.’s Covid-19 vaccine results are expected imminently and scientists will be scanning the data to gauge the shot’s promise. At the same time, day traders -- who’ve snapped up shares since March -- will be looking for the more than $7 billion surge in value to hold.
Vaccine candidates presented so far have detailed initial patient antibody and T-cell responses and compared them with levels seen in patients who have recovered from the virus. Investors will be looking for those initial immune-system responses when Novavax reveals its data, likely sometime next week.